Search

Displaying results 4601 - 4610 of 10000 in total
  1. Drug

    HEPES

    go.drugbank.com/drugs/DB16872
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Ametantrone

    go.drugbank.com/drugs/DB21078
    Experimental

    Ametantrone is a small molecule drug. Ametantrone has a monoisotopic molecular weight of 412.21 Da.

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    MDX-214

    go.drugbank.com/drugs/DB06110
    Experimental

    MDX-214 consists of recombinant human epidermal growth factor (EGF) genetically linked to a fully human antibody fragment that is designed to activate cytotoxic killing of cancer cells by immune effector cells. It is developed for the tr...

  4. Drug

    Relacatib

    go.drugbank.com/drugs/DB06367
    Investigational

  5. Drug

    Apolizumab

    go.drugbank.com/drugs/DB06467
    Investigational

    Apolizumab is a humanized monoclonal antibody that is being studied as a treatment for hematologic cancers.

  6. Drug

    VT-111

    go.drugbank.com/drugs/DB05646
    Investigational

    VT-111 is a 55 kDa secreted glycoprotein belonging to a superfamily of proteins called SERPINS, which share a general structure and mechanism for proteinase inhibition.

  7. Drug

    Pucotenlimab

    go.drugbank.com/drugs/DB17552
    ApprovedInvestigational

    It received its first global approval in China in July 2022 for the treatment of solid tumours.[A257296] It is being investigated in other cancers.

  8. Drug

    Ticalopride

    go.drugbank.com/drugs/DB06422
    Experimental

  9. Drug

    ALGRX 1207

    go.drugbank.com/drugs/DB06482
    Experimental

    ALGRX 1207 entered clinical trials for cutaneous neuropathic pain, such as chemotherapy-induced neuropathy, in 2006. It was being developed by Anesiva, but trials have halted.

  10. Drug

    Dilmapimod

    go.drugbank.com/drugs/DB12140
    Investigational

    Dilmapimod (SB-681323) is a p38 MAP-kinase inhibitor that has potential uses in inflammatory conditions such as RA (Rheumatoid Arthritis). … Previous p38 MAP-kinase inhibitors have been hindered in development by liver toxicity. Methotrexate (common treatment for RA patients) also has potential liver toxicity.}